Guggenheim Keeps Their Buy Rating on AstraZeneca (AZN)

Guggenheim analyst Seamus Fernandez reiterated a Buy rating on AstraZeneca yesterday and set a price target of £162.00.

TipRanks Welcomes a New ETF – NYSE:RANK

• TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
• RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Fernandez covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Amylyx Pharmaceuticals Inc, and Arcutis Biotherapeutics. According to TipRanks, Fernandez has an average return of 32.4% and a 67.44% success rate on recommended stocks.

In addition to Guggenheim, AstraZeneca also received a Buy from Citi’s Graham Parry in a report issued today. However, on the same day, Deutsche Bank maintained a Sell rating on AstraZeneca (LSE: AZN).

Based on AstraZeneca’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of p15.29 billion and a net profit of p3.08 billion. In comparison, last year the company earned a revenue of p13.96 billion and had a net profit of p3 billion

Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AZN in relation to earlier this year.